Thermoseed hyperthermia treatment of mammary orthotopic transplantation tumors in rats and impact on immune function

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 973-979

  Ouyang, Weiwei ^a,b   Gao, Fuping ^b   Wang, Lufang ^b,c   Xie, Xiaoxue ^a,b   Lei, Fenglin ^b   Zhou, Jumei ^a,b   Liao, Yuping ^a   Zhong, Meizuo ^a   Tang, Jintian ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Hyperthermia; Immunological function; Mammary tumor; Thermoseed

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER SURVIVAL; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HYPERTHERMIC THERAPY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; RAT; SURVIVAL TIME; THERMOSEED HYPERTHERMIA; TISSUE NECROSIS; TUMOR CELL; TUMOR VOLUME; WALKER CARCINOMA;

ANIMALS; CELL SEPARATION; COPPER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HSP70 HEAT-SHOCK PROTEINS; HYPERTHERMIA, INDUCED; IMMUNOHISTOCHEMISTRY; IMPLANTS, EXPERIMENTAL; INTERFERON-GAMMA; INTERLEUKIN-2; MAGNETIC FIELD THERAPY; MAMMARY NEOPLASMS, EXPERIMENTAL; NICKEL; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, WISTAR; T-LYMPHOCYTES;

EID: 77957354599     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.973     Document Type: Article

References (34)

1. Steeves RA, Murray TG, Moros EG, Boldt HC, Mieler WF and Paliwal BR: Concurrent ferromagnetic hyperthermia and I-125 brachytherapy in a rabbit choroidal melanoma model. Int J Hyperthermia 8: 443-449, 1992.
2. Rehman J, Landman J, Tucker RD, Bostwick DG, Sundaram CP and Clayman RV: Ferromagnetic self-regulating reheatable thermal rod for in situ tissue ablation. J Endourol 16: 523-531, 2002.
3. Tucker RD, Platz CE, Huidobro C and Larson T: Interstitial thermal therapy in patients with localized prostate cancer: histologic analysis. Urology 60: 166-169, 2002.
4. Akagi M, Tsuboyama T, Ikenaga M, Matsusue Y, Hiraoka M and Nakamura T: Anti-tumour effects of localized hyperthermia on an experimental bone tumour using an intramedullary nail. Int J Hyperthermia 13: 387-400, 1997.
5. Murray TG, O'Brien JM, Steeves RA, et al: Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol 114: 1376-1381, 1996.
6. Stea B, Rossman K, Kittelson J, Shetter A, Hamilton A and Cassady JR: Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: a comparative survival analysis. Int J Radiat Oncol Biol Phys 30: 591-600, 1994.
7. Master VA, Shinohara K and Carroll PR: Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. J Urol 172: 2197-2202, 2004.
8. Tucker RD, Huidobro C and Larson T: Ablation of stage T-1/T-2 prostate cancer with permanent interstitial temperature selfregulating rods. J Endourol 19: 865-867, 2005.
9. Johannsen M, Thiesen B, Jordan A, et al: Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic dunning R3327 rat model. Prostate 64: 283-292, 2005.
10. Guo J, Zhu J, Sheng XN, et al: Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 120: 2418-2425, 2007.
11. Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J and Wu F: Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery 145: 286-293, 2009.
12. Rong Y and Mack P: Apoptosis induced by hyperthermia in Dunn osteosarcoma cell line in vitro. Int J Hyperthermia 16: 19-27, 2000.
13. Saito H, Mitobe K, Ito A, et al: Self-regulating hyperthermia induced using thermosensitive ferromagnetic material with a low Curie temperature. Cancer Sci 99: 805-809, 2008.
14. Thompson JF and Kam PCA: Current status of isolated limb infusion with mild hyperthermia for melanoma. Int J Hyperthermia 24: 219-225, 2008.
15. Atmaca A, Al-Batran SE, Neumann A, Kolassa Y, Jager D, Knuth A and Jager E: Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study. Gynecol Oncol 112: 384-388, 2009.
16. Park S, Cadeddu JA and Shingleton WB: Oncologic outcomes for ablative therapy of kidney cancer. Curr Urol Rep 8: 31-37, 2007. (Pubitemid 46202656)
17. Kawasaki H, Toyoda M, Shinohara H, et al: Expression of survivin correlates with apoptosis, proliferation and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032, 2001.
18. Johannsen M, Gneueckow U, Thiesen B, et al: Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging and three-dimensional temperature distribution. Eur Urol 52: 1653-1662, 2007.
19. Kamisawa T, Tu YY, Egawa N, Karasawa K, Matsuda T, Tsuruta K and Okamoto A: Thermo-chemo-radiotherapy for advanced bile duct carcinoma. World J Gastroenterol 11: 4206-4209, 2005. (Pubitemid 41086872)
20. Akiyama S, Kawasaki S, Kodera Y, Hibi K, Kato S, Ito K and Nakao A: A new method of thermo-chemotherapy using a stent for patients with esophageal cancer. Surg Today 36: 19-24, 2006.
21. Yu KD, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ and Shao ZM: Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol 14: 2502-2509, 2007.
22. Hall-Craggs MA and Vaidya JS: Minimally invasive therapy for the treatment of breast tumours. Eur J Radiol 42: 52-57, 2002.
23. Singletary SE: Minimally invasive ablation techniques in breast cancer treatment. Ann Surg Oncol 9: 319-320, 2002.
24. Bantis A, Giannopoulos A, Gonidi M, et al: Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathol 15: 25-31, 2004.
25. Li DP, Li H, Zhang PY, et al: Heat shock fusion protein induces both specific and non-specific anti-tumor immunity. Eur J Immunol 36: 1324-1336, 2006.
26. Zhang HG, Mehta K, Cohen P and Guha C: Hyperthermia on immune regulation: a temperature's story. Cancer Lett 271: 191-204, 2008.
27. Tobian AAR, Canaday DH and Harding CV: Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4(+) T cells. J Immunol 173: 5130-5137, 2004.
28. Todryk S, Melcher AA, Hardwick N, et al: Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163: 1398-1408, 1999.
29. Chamuleau MED, Ossenkoppele GJ and van de Loosdrecht AA: MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology 211: 619-625, 2006.
30. Mafune K and Tanaka Y: Influence of multimodality therapy on the cellular immunity of patients with esophageal cancer. Ann Surg Oncol 7: 609-616, 2000.
31. Ito A, Tanaka K, Kondo K, et al: Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 94: 308-313, 2003.
32. Kominsky S, Johnson HM, Bryan G, Tanabe T, Hobeika AC, Subramaniam PS and Torres B: IFN gamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Oncogene 17: 2973-2979, 1998.
33. Yao L, Pike SE, Setsuda J, et al: Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96: 1900-1905, 2000.
34. Kramer G, Steiner GE, Grobl M, et al: Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells. Prostate 58: 109-120, 2004.